Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FXRQ8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,250
Award facts
- Contract value 100% obligated
- $16,249.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order awards $16,249.95 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. The contract is funded by the Defense Logistics Agency (DLA), which manages logistics and supply chain operations for the Department of Defense. The award employs firm fixed pricing with an ultimate completion date of July 17, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA's SPE2DB program, a $499.999 billion single-award vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products to support medical supply needs across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with a demonstrated track record of delivering diverse pharmaceutical products to military health facilities. The company's federal contract portfolio spans multiple therapeutic categories, including specialty medications such as Botox, Tecentriq, Xtandi, and various vaccines and injectable products. As the prime contractor on this award, DMS Pharmaceutical Group will deliver Stelara, a biologic immunosuppressant medication used in the treatment of autoimmune conditions, directly to federal healthcare operations. The firm fixed-price delivery order structure provides cost certainty for government procurement while enabling efficient distribution of essential pharmaceutical supplies to Department of Defense medical facilities.
Quick answers
Who was awarded contract SPE2DB25FXRQ8?
SPE2DB25FXRQ8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on June 25, 2025.
How much is contract SPE2DB25FXRQ8 worth?
The government has obligated $16,250 on SPE2DB25FXRQ8.
Is contract SPE2DB25FXRQ8 an order under another contract?
Yes. SPE2DB25FXRQ8 is a delivery order under SPE2DB24D9131, an indefinite delivery contract.
Was contract SPE2DB25FXRQ8 competed?
The extent of competition for SPE2DB25FXRQ8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award